Sprycel 20 mg, 50 mg, 70 mg and 100 mg Tablets.
PDF Leaflet Revision Date: 12 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adults with Ph+ CML and Ph+ ALL.
Dosage (summary)
Chronic phase CML: 100 mg once daily; Advanced phase CML/Ph+ ALL: 70 mg twice daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Grapefruit juice
Contraindications
- Hypersensitivity to dasatinib
- Concomitant use of H2 antagonists or PPIs
Common side effects
- Myelosuppression
- Fluid retention
- Diarrhea
- Nausea
- Fatigue
Counselling Points
- Take with or without food
- Avoid grapefruit
- Monitor for bleeding or fluid retention
Serious warnings
- Myelosuppression
- Severe bleeding events
- Fluid retention
- Cardiac adverse reactions
Important Disclaimer
The Sprycel 20 mg, 50 mg, 70 mg and 100 mg Tablets. professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
